PAX Stock Overview
Develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for PAX from our risk checks.
Paxman AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 55.80 |
| 52 Week High | SEK 60.00 |
| 52 Week Low | SEK 22.00 |
| Beta | 0.83 |
| 11 Month Change | 4.49% |
| 3 Month Change | 19.49% |
| 1 Year Change | 64.12% |
| 33 Year Change | 12.05% |
| 5 Year Change | -3.79% |
| Change since IPO | 411.93% |
Recent News & Updates
Results: Paxman AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Aug 24
Paxman (STO:PAX) Might Have The Makings Of A Multi-Bagger
Aug 07After Leaping 28% Paxman AB (publ) (STO:PAX) Shares Are Not Flying Under The Radar
Jul 18Recent updates
Results: Paxman AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Aug 24Paxman (STO:PAX) Might Have The Makings Of A Multi-Bagger
Aug 07After Leaping 28% Paxman AB (publ) (STO:PAX) Shares Are Not Flying Under The Radar
Jul 18Even With A 29% Surge, Cautious Investors Are Not Rewarding Paxman AB (publ)'s (STO:PAX) Performance Completely
May 24Does Paxman (STO:PAX) Have A Healthy Balance Sheet?
Dec 23Paxman (STO:PAX) Shareholders Will Want The ROCE Trajectory To Continue
Aug 25Paxman AB (publ) (STO:PAX) Could Be Riskier Than It Looks
Jun 01Does Paxman (STO:PAX) Have A Healthy Balance Sheet?
Nov 20Is Paxman (STO:PAX) A Risky Investment?
Mar 07Paxman (STO:PAX) Is Making Moderate Use Of Debt
Mar 15Are Insiders Buying Paxman AB (publ) (STO:PAX) Stock?
Jan 22Reflecting on Paxman's (STO:PAX) Share Price Returns Over The Last Year
Dec 18
Shareholder Returns
| PAX | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 10.3% | 1.6% | 2.5% |
| 1Y | 64.1% | 15.1% | 19.4% |
Return vs Industry: PAX exceeded the Swedish Medical Equipment industry which returned 12.6% over the past year.
Return vs Market: PAX exceeded the Swedish Market which returned 18.3% over the past year.
Price Volatility
| PAX volatility | |
|---|---|
| PAX Average Weekly Movement | 5.5% |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 12.0% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: PAX has not had significant price volatility in the past 3 months.
Volatility Over Time: PAX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 102 | Richard Paxman | paxmanscalpcooling.com |
Paxman AB (publ), together with its subsidiaries, develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment worldwide. It serves various cancer centers and hospitals. The company has a research collaboration agreement with National University Hospital, Singapore for the development of portable cooling and compression device.
Paxman AB (publ) Fundamentals Summary
| PAX fundamental statistics | |
|---|---|
| Market cap | SEK 1.06b |
| Earnings (TTM) | SEK 28.64m |
| Revenue (TTM) | SEK 248.01m |
37.0x
P/E Ratio4.3x
P/S RatioIs PAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PAX income statement (TTM) | |
|---|---|
| Revenue | SEK 248.01m |
| Cost of Revenue | SEK 80.16m |
| Gross Profit | SEK 167.85m |
| Other Expenses | SEK 139.21m |
| Earnings | SEK 28.64m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 15, 2024
| Earnings per share (EPS) | 1.51 |
| Gross Margin | 67.68% |
| Net Profit Margin | 11.55% |
| Debt/Equity Ratio | 9.1% |
How did PAX perform over the long term?
See historical performance and comparison